Last reviewed · How we verify
Restasis (cyclosporine 0.05%)
Restasis (cyclosporine 0.05%) is a immunosuppressant Small molecule drug developed by DH Bio Co., Ltd.. It is currently in Phase 3 development for Treatment of chronic dry eye syndrome.
Restasis works by increasing tear production in patients with dry eye syndrome.
Restasis works by increasing tear production in patients with dry eye syndrome. Used for Treatment of chronic dry eye syndrome.
At a glance
| Generic name | Restasis (cyclosporine 0.05%) |
|---|---|
| Sponsor | DH Bio Co., Ltd. |
| Drug class | immunosuppressant |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Restasis contains cyclosporine, an immunosuppressant that helps to increase tear production by reducing inflammation in the lacrimal gland. This leads to improved tear quality and quantity, alleviating symptoms of dry eye syndrome.
Approved indications
- Treatment of chronic dry eye syndrome
Common side effects
- Eye irritation
- Headache
- Eye pain
Key clinical trials
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) (NA)
- Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT (NA)
- Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom (NA)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- CsA vs MMC for Preventing Pterygium Recurrence (NA)
- Cyclosporine Vs Steroids in DRESS (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Restasis (cyclosporine 0.05%) CI brief — competitive landscape report
- Restasis (cyclosporine 0.05%) updates RSS · CI watch RSS
- DH Bio Co., Ltd. portfolio CI
Frequently asked questions about Restasis (cyclosporine 0.05%)
What is Restasis (cyclosporine 0.05%)?
How does Restasis (cyclosporine 0.05%) work?
What is Restasis (cyclosporine 0.05%) used for?
Who makes Restasis (cyclosporine 0.05%)?
What drug class is Restasis (cyclosporine 0.05%) in?
What development phase is Restasis (cyclosporine 0.05%) in?
What are the side effects of Restasis (cyclosporine 0.05%)?
What does Restasis (cyclosporine 0.05%) target?
Related
- Drug class: All immunosuppressant drugs
- Target: All drugs targeting calcineurin
- Manufacturer: DH Bio Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of chronic dry eye syndrome
- Compare: Restasis (cyclosporine 0.05%) vs similar drugs
- Pricing: Restasis (cyclosporine 0.05%) cost, discount & access